Abstract
Helicobacter pylori infection is a major cause of many diseases of the gastrointestinal tract, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. It is estimated that more than half of the human race is affected by this organism. Although effective treatments are available which will eliminate the organism in about 90percent of cases in developed countries, the pandemic occurrence of Helicobacter pylori infection coupled with its ability to develop resistance to our current arsenal of antimicrobial regimens and subsequently reinfect patients makes the pathogenic potential of this microorganism a major global health concern. Provided is a review of the current and evolving therapeutic regimens used in the eradication of Helicobacter pylori, the difficulties associated with in vitro drug screening, as well as potentially new therapeutic targets. In addition, the discovery, the unique physiology, biochemistry, and pathogenicity of this remarkable microorganism is examined.
Keywords: Helicobacter pylori, Gastritis, Non-ulcer dyspepsia, Peptic ulcer disease, Gastric cancers, Compylobacter jejuni, Adhesion factor, Urease, Inflammation, VacA
Current Pharmaceutical Design
Title: Helicobacter pylori Current Chemotherapy and New Targets for Drug Design
Volume: 7 Issue: 5
Author(s): John S. Williamson
Affiliation:
Keywords: Helicobacter pylori, Gastritis, Non-ulcer dyspepsia, Peptic ulcer disease, Gastric cancers, Compylobacter jejuni, Adhesion factor, Urease, Inflammation, VacA
Abstract: Helicobacter pylori infection is a major cause of many diseases of the gastrointestinal tract, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. It is estimated that more than half of the human race is affected by this organism. Although effective treatments are available which will eliminate the organism in about 90percent of cases in developed countries, the pandemic occurrence of Helicobacter pylori infection coupled with its ability to develop resistance to our current arsenal of antimicrobial regimens and subsequently reinfect patients makes the pathogenic potential of this microorganism a major global health concern. Provided is a review of the current and evolving therapeutic regimens used in the eradication of Helicobacter pylori, the difficulties associated with in vitro drug screening, as well as potentially new therapeutic targets. In addition, the discovery, the unique physiology, biochemistry, and pathogenicity of this remarkable microorganism is examined.
Export Options
About this article
Cite this article as:
Williamson S. John, Helicobacter pylori Current Chemotherapy and New Targets for Drug Design, Current Pharmaceutical Design 2001; 7 (5) . https://dx.doi.org/10.2174/1381612013397979
DOI https://dx.doi.org/10.2174/1381612013397979 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Ginger for Prevention or Treatment of Drug-Induced Nausea and Vomiting
Current Clinical Pharmacology Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Fruit as Potent Natural Antioxidants and Their Biological Effects
Current Pharmaceutical Biotechnology Editorial
Current Medical Imaging Medicinal Importance of Flavonoid “Eupatorin” in the Health Sectors: Therapeutic Benefit and Pharmacological Activities Through Scientific Data Analysis
Current Chinese Science Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry SDH Genes: From Glomic Tumours to Pheochromocytomas
Current Hypertension Reviews Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry From the Sea to Anticancer Therapy
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology